Curetero (Rocuronium) for IV Injection

Rocuronium (Curetero) is a rapid-onset neuromuscular blocking agent essential for modern anesthesia practice. This potent steroidal compound selectively antagonizes acetylcholine at the neuromuscular junction, inducing temporary skeletal muscle paralysis to facilitate endotracheal intubation, optimize surgical exposure, and enable mechanical ventilation in critical care settings.

Pharmacologically, rocuronium demonstrates a quick onset time of 30–40 seconds at standard doses (0.6–1.2 mg/kg IV), making it the preferred choice for rapid sequence intubation in emergency and elective procedures. Its intermediate duration of action (30–40 minutes) and predictable metabolism via hepatic and renal routes provide clinicians with reliable, dose-dependent neuromuscular blockade without significant organ accumulation.

Clinical advantages include minimal histamine release compared to earlier agents, hemodynamic stability in most patients, and compatibility with modern neuromuscular monitoring devices. Reversal with sugammadex offers rapid decuracization, reducing postoperative residual neuromuscular blockade and associated complications.

Indicated for use in balanced general anesthesia, rapid sequence induction, and prolonged surgical procedures requiring sustained neuromuscular paralysis. Suitable for pediatric and adult populations when dosed appropriately by body weight and clinical status.

Store between 2–8°C (refrigerated) or at room temperature per product specifications. Handle with care to maintain sterility and efficacy. Curetero rocuronium represents a trusted, evidence-based standard for anesthesia delivery in hospitals, surgical centers, and critical care environments worldwide.